ABSTRACT
A leukotriene biosynthesis inhibitor (MK886), a platelet-activating factor (PAF)-receptor antagonist (WEB 2086), a recombinant human interleukin-1 receptor antagonist (IL-1ra) and a polyclonal antibody to recombinant bovine IL-1 beta (anti-rBoIL-1 beta) was used to investigate the involvement of leukotrienes, PAF and IL-1 beta during endotoxin-induced inflammation in the bovine teat cistern. Endotoxin alone was infused into one teat cistern and endotoxin in combination with an inhibitor/antagonist was infused into another teat cistern of the same animal. Teat cistern samples were taken before infusion and at 3.5 and 7 h after infusion, and the numbers of neutrophils were counted. Saline infusion was used as control. The inhibitors/antagonists were also tested in combination with leukotriene B4 (LTB4), PAF and rBoIL-1 beta, respectively. MK886 or WEB 2086 significantly reduced the accumulation of neutrophils mainly between 3.5 and 7 h after infusion, indicating roles for leukotrienes, probably LTB4, and PAF in neutrophil accumulation during endotoxin-induced inflammation. As WEB 2086 also reduced cell accumulation between 0 and 3.5 h, PAF was implicated also in the early influx of neutrophils. WEB 2086 almost completely inhibited PAF-induced cell accumulation between 0 and 3.5 h. LTB4 did not induce significant cell accumulation in the teat cistern. IL-1ra did not affect endotoxin-induced neutrophil accumulation whereas anti-rBoIL-1 beta reduced total cell accumulation and, to some degree, accumulation between 0 and 3.5 h after infusion. Infusion of IL-1ra significantly inhibited cell accumulation induced by rBoIL-1 beta. Anti-rBoIL-1 beta also significantly reduced neutrophil accumulation induced by rBoIL-1 beta, but to a lesser degree. The results suggest roles for leukotrienes, most likely LTB4, and PAF, and to a lesser extent IL-1 beta, during endotoxin-induced neutrophil migration into the bovine teat cistern. The potential of the inhibitors/antagonists as therapeutic agents for bovine mastitis should be investigated.
Subject(s)
Adjuvants, Immunologic/pharmacology , Blood Coagulation Factors/antagonists & inhibitors , Endotoxins , Interleukin-1/antagonists & inhibitors , Leukotriene Antagonists , Mammary Glands, Animal/immunology , Mastitis, Bovine/immunology , Platelet Activating Factor , Animals , Azepines/immunology , Cattle , Female , Fibrinolytic Agents/immunology , Humans , Indoles/immunology , Interleukin 1 Receptor Antagonist Protein , Interleukin-1/immunology , Lipoxygenase Inhibitors/immunology , Mammary Glands, Animal/drug effects , Mastitis, Bovine/etiology , Platelet Aggregation Inhibitors/immunology , Recombinant Proteins/immunology , Sialoglycoproteins/immunology , Triazoles/immunologyABSTRACT
BACKGROUND: A very small number of patients with asthma show symptomatic improvement after administration of aspirin and other cyclooxygenase inhibitors. The clinical features of such patients with so-called aspirin-relieved asthma are similar to those with aspirin-induced asthma, but the pathogenesis is unclear. METHODS: We encountered one confirmed aspirin-relieved asthma patient and investigated the effects of cyclooxygenase and lipoxygenase inhibitors on his condition. RESULTS: Our patient showed a marked improvement of the forced expiratory volume in one second (FEV1) after administration of aspirin and three other cyclooxygenase inhibitors (indomethacin, mefenamic acid, and ketoprofen). A 5-lipoxygenase inhibitor (AA861, Takeda, Japan), however, evoked acute asthma, and repeated administration of this drug resulted in some desensitization, but not complete tolerance. CONCLUSIONS: These results suggest an altered balance of arachidonic acid metabolism may play a critical role in the pathophysiology of aspirin-relieved asthma.
